IART Integra Lifesciences Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IART

Price (delayed)

$14.265

Market cap

$1.11B

P/E Ratio

83.91

Dividend/share

N/A

EPS

$0.17

Enterprise value

$2.86B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 54

At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative ...

Highlights
IART's EPS has surged by 103% year-on-year
Integra Lifesciences Holdings's net income has soared by 103% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.integralife.com
Peers: SYK TFX XRAY CNMD

Key stats

What are the main financial stats of IART

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
-3.42%
1 week
1.03%
1 month
2.04%
1 year
17.99%
YTD
14.86%
QTD
-12.38%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.66B
Gross profit
$867.46M
Operating income
$72.7M
Net income
$13.01M
Gross margin
52.4%
Net margin
0.8%
The operating income has surged by 115% year-on-year and by 11% since the previous quarter
IART's operating margin has soared by 115% year-on-year and by 10% since the previous quarter
The net margin has soared by 103% year-on-year
Integra Lifesciences Holdings's net income has soared by 103% YoY

Price vs fundamentals

How does IART's price correlate with its fundamentals

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
IART P/E details
P/E
83.91
P/B
1.04
P/S
0.67
EV/EBIT
25
EV/EBITDA
10.66
EV/Sales
1.73
IART's EPS has surged by 103% year-on-year
The P/B is 40% lower than the 5-year quarterly average of 1.8 but 8% higher than the last 4 quarters average of 1.0
The equity has increased by 2.8% year-on-year and by 2.2% since the previous quarter
The price to sales (P/S) is 59% less than the 5-year quarterly average of 1.7

Efficiency

How efficient is Integra Lifesciences Holdings business performance
IART's return on sales has surged by 124% year-on-year and by 23% since the previous quarter
IART's return on invested capital has surged by 121% year-on-year and by 25% since the previous quarter
IART's ROA has soared by 103% YoY
Integra Lifesciences Holdings's return on equity has surged by 103% YoY

Dividends

What is IART's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 44% higher than its total liabilities
IART's quick ratio is up by 16% YoY and by 3.7% from the previous quarter
The current ratio has grown by 15% year-on-year
The debt is 88% greater than the equity
Integra Lifesciences Holdings's debt to equity has decreased by 4.1% QoQ and by 2.6% YoY
The equity has increased by 2.8% year-on-year and by 2.2% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.